MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Experimental therapeutics"

  • 2025 International Congress

    Modulation of working memory in prodromal DLB by non-invasive brain stimulation of the striatum and cerebellum

    I. Rektorová, M. Pupikova, . Gajdoš (Brno, Czech Republic)

    Objective: We aimed to modulate working memory (WM) in patients with MCI with Lewy bodies (MCI-LB) by non-invasive stimulation of the striatum with or without…
  • 2025 International Congress

    Repeated Scanning Ultrasound in an Alpha-synuclein Preformed Fibril model

    V. Purrer, K. Roffey, G. Richter-Stretton, J. Song, G. Leinenga, L. Chen, E. Albornoz Balmaceda, J. Götz (St Lucia, Australia)

    Objective: To investigate the therapeutic potential of repeated scanning ultrasound (SUS)-mediated blood-brain barrier (BBB) opening in a mouse model of Parkinson’s disease (PD). Background: PD…
  • 2025 International Congress

    Impact of Gastrointestinal Dysfunction Symptoms on Psychomotor Recovery Following 8-Week Aerobic Interval Training in Parkinson’s Disease – Preliminary Results

    K. Lorek, K. Markowska, A. Bereza, E. Koziorowska, S. Budrewicz, P. Nowakowski, S. Chomiak (Wroclaw, Poland)

    Objective: To investigate the impact of gastrointestinal dysfunction symptoms (GIDS) on psychomotor recovery following 8-week aerobic interval training (AIT) in Parkinson's disease (PD). Background: GIDS…
  • 2025 International Congress

    Honey products in Parkinson’s disease – randomized placebo-controlled double-blind pilot study

    T. Endo, K. Toyooka, T. Matsumura, C. Mori, T. Saito, T. Saito, S. Sakoda (Toyonaka, Japan)

    Objective: The purpose of this study is to examine whether consumption of honey products can improve symptoms and their diurnal fluctuations in patients with Parkinson's…
  • 2025 International Congress

    Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of Vent-02, a Novel CNS-Penetrant NLRP3 Inhibitor for the Treatment of Parkinson’s Disease

    A. Matta, X. Valencia, L. Warner, K. Pike, C. Winters, L. Smidt, M. Moerland, O. Spiegelstein (Waltham, USA)

    Objective: The objectives of this first-in-human study were to assess the safety, tolerability, pharmacokinetics (PK), food-effect and pharmacodynamics of VENT-02 in healthy volunteers Background: Vent-02…
  • 2025 International Congress

    Retention & Safety in a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo (TOPAZ) in Persons with Neurodegenerative Parkinsonism (NDP)

    C. Tanner, N. Luthra, S. Goldman, R. Zuzuarregui, E. Brown, C. Meng, J. Perkins, L. Racelo, T. Hue, C. Schambach, D. Kriesel, H. Barnes, T. Stiep, I. Bledsoe, P. Ranola, M. Schwarzschild, R. Dorsey, A. Espay, S. Krischer, C. Comella, M. Siddiqui, F. Gao, M. Ledoux, E. Byrd, I. Litvan, N. Mcfarland, K. Mitchell, D. Standaert, J. Beck, K. Williams, M. Drake, D. Bauer, K. Lyles, S. Cummings, THE. Topaz Study-Team (San Francisco, USA)

    Objective: To assess retention and safety in the ongoing TOPAZ trial, NCT03924414 Background: People with NDP face a four-fold increased fracture risk, yet preventive treatment…
  • 2025 International Congress

    Solengepras: An Investigational Therapy with Potential Benefits on Functional and Non-Motor Measures in Parkinson’s Disease (PD)

    S. Isaacson, K. Chou, H. Sarva, S. Merchant, C. Scholl, M. Charles, N. Brice, L. Dawson, M. Carlton, S. Vaidya, K. Kieburtz, R. Hauser, A. Ellenbogen (Ann Arbor, USA)

    Objective: Solengepras is a GPR6-inhibitor that is being studied as an investigational treatment for Parkinson’s Disease (PD). Background: GPR6 is a novel G-protein-coupled receptor found…
  • 2025 International Congress

    Impact of Allogeneic Mesenchymal Stem Cells in Motor and Non-Motor Symptoms of Parkinson’s Disease: A Phase 2 Randomized Trial

    M. Schiess, J. Martinez-Lemus, T. Thomas, E. Tharp, C. Onuigbo, J. Suescun, T. Ellmore, T. Le, E. Rodarte-Rascon, R. Ritter Iii, C. Green (Houston, USA)

    Objective: To assess the efficacy of repeated intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) infusions in reducing motor and non-motor symptoms in people…
  • 2025 International Congress

    Impact of Over-the-counter Cannabidiol Products on Cognition During the Course of Parkinson’s Disease

    A. López Lobato, D. Náfate Wences, A. Hernández Medrano, A. Cervantes Arriaga, M. Rodriguez Violante (Mexico, Mexico)

    Objective: To evaluate the association between Cannabidiol (CBD) usage and cognitive performance, measured by The Montreal Cognitive Assessment (MoCA) in people living with Parkinson's Disease…
  • 2025 International Congress

    Fecal Microbiota Transplantation for Parkinson’s Disease: A Systematic Review and Meta-Analysis

    A. Menegaz Ms, J. Martinez-Lemus Md, í. Barros Andrade, F. Tamashiro Ms, F. Westphal Filho, P. Moss Ms, J. Patiño Md, M. Schiess Md (Houston, USA)

    Objective: To assess Fecal Microbiota Transplantation (FMT) efficacy in improving Parkinson’s disease (PD) symptoms. Background: Dysregulation of the microbiome–gut–brain axis is a key pathophysiological mechanism…
  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28953 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley